來源:[1] 葛蘭素史克(GSK)哮喘藥物depemokimab獲批在望 - pharmaphorum (https://pharmaphorum.com/news/gsk-closes-appr ...)[2] LEO Pharma向EMA提交Anzupgo®青少年適應症擴展申請 - BioSpace (https://www.biospace.com/press-releases/leo-p ...)[3] Milestone漫長的監管之路以Cardamyst獲批告終 - BioSpace (https://www.biospace.com/fda/milestones-long- ...)